NCCN Acute Myeloid Leukemia Panel

On behalf of Daiichi Sankyo, Inc., I would like to inform you that quizartinib, an investigational FLT3 inhibitor, is under FDA Priority Review for the treatment of adult patients with relapsed/refractory FLT3-ITD AML. The PDUFA action date is August 25, 2019. The NDA submission is based on the results of the Phase 3 randomized study QuANTUM-R. If approved, a communication with study data and the full Prescribing Information will be submitted to inform the NCCN AML panel.

Sincerely,

Dan Liang, Pharm.D.

References (enclosed)